Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc - Paris, France
This video was recorded at the EAS in Maastricht, the Netherlands, on May 29, 2019.
John Chapman is Research Professor at the Sorbonne University, is affiliated with the Endocrinology-Metabolism Division of the Pitié-Salpêtrière University Hospital, and is Director Emeritus of the National Institute for Health and Medical Research (INSERM) in Paris, France.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.